AstraZeneca PLC (AZN)vsEvotec SE ADR (EVO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
EVO
Evotec SE ADR
$3.11
+5.78%
HEALTHCARE · Cap: $1.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7351% more annual revenue ($58.74B vs $788.37M). AZN leads profitability with a 17.4% profit margin vs -13.1%. EVO appears more attractively valued with a PEG of 1.42. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
EVO
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for EVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -11.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : EVO
The strongest argument for EVO centers on Price/Book. Revenue growth of 14.5% demonstrates continued momentum. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while EVO is a turnaround play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.24 — expect wider price swings.
EVO is growing revenue faster at 14.5% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 43/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology firm headquartered in Hamburg, Germany, specializing in end-to-end drug discovery and development solutions for the pharmaceutical and biotech industries. The company employs a synergistic approach, collaborating with both established pharmaceutical giants and cutting-edge academic institutions to accelerate the advancement of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline of projects, Evotec is strategically positioned to leverage emerging opportunities in the biopharmaceutical landscape, reinforcing its essential role in driving healthcare innovation and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?